Skip to main content
CRIS logo

CRIS · Curis Inc · Earnings Calls, Transcripts & Webcasts

Track CRIS — free
$0.43 -0.04 (-9.03%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$4.06M
Shares
9.51M
Volume · Nov 20 531.09K Avg daily vol (3M) 4.27M

Curis Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Curis Inc (CRIS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-12
Curis Inc (CRIS) Q3 2026 Earnings Call Transcript
Positive tone CLL proof-of-concept study PCNSL registrational enrollment PCNSL clinical efficacy
Net income
−$8.12M
Diluted EPS
$-1.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Curis Inc (CRIS) Q1 2026 Earnings Call Transcript
Positive tone TakeAim CLL proof-of-concept study TakeAim Lymphoma / PCNSL registrational study Financial position and runway
Revenue
$0
▼ 100% YoY
Diluted EPS
$-25.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Curis Inc (CRIS) Q4 2025 Earnings Call Transcript
Confident tone Emavusertib + ibrutinib in CLL proof-of-concept TakeAim Lymphoma / PCNSL registrational study Resource prioritization and AML deferral
Revenue
$1.14M*
▼ 66% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Curis Inc (CRIS) Q3 2025 Earnings Call Transcript
Positive tone CLL Program Expansion PCNSL (Primary CNS Lymphoma) TakeAim Lymphoma Study AML Triplet Study (Aza-Ven + Emavusertib)
Revenue
$3.18M
▲ 8.4% YoY
Diluted EPS
$-9.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Curis Inc (CRIS) Q2 2025 Earnings Call Transcript
Confident tone TakeAim Lymphoma / PCNSL study CLL proof-of-concept study AML relapsed/refractory registrational study
Revenue
$2.75M
▲ 8% YoY
Diluted EPS
$-13.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Curis Inc (CRIS) Q1 2025 Earnings Call Transcript
Positive tone Emavusertib in PCNSL (TakeAim Lymphoma study) Emavusertib in AML Broader NHL / pipeline expansion strategy
Revenue
$2.38M
▲ 14.1% YoY
Diluted EPS
$-25.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Curis Inc (CRIS) Q4 2024 Earnings Call
Revenue
$3.35M*
▲ 24.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Curis Inc (CRIS) Q3 2024 Earnings Call Transcript
Positive tone PCNSL study with ibrutinib combination FDA regulatory engagement and accelerated approval TakeAim Leukemia (AML) data
Revenue
$2.93M
▲ 3.5% YoY
Diluted EPS
$-34.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Curis Inc (CRIS) Q2 2024 Earnings Call Transcript
Confident tone TakeAim Leukemia study in AML TakeAim Lymphoma / PCNSL study IRAK4 mechanism and differentiation
Revenue
$2.55M
▲ 15.9% YoY
Diluted EPS
$-40.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Curis Inc (CRIS) Q1 2024 Earnings Call Transcript
Confident tone FLT3 mutation benchmark positioning Emavusertib clinical progress in AML and lymphoma Regulatory path and FDA discussions
Revenue
$2.09M
▼ 9.2% YoY
Diluted EPS
$-41.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-08
Curis Inc (CRIS) Q4 2023 Earnings Call Transcript
Confident tone Emavusertib leukemia program (AML) Primary CNS lymphoma (PCNSL) program Solid tumor expansion (melanoma/IIT)
Revenue
$2.70M*
▼ 6.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Curis Inc (CRIS) Q3 2023 Earnings Call Transcript
Revenue
$2.83M
▲ 0.3% YoY
Diluted EPS
$-42.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Curis Inc (CRIS) Q2 2023 Earnings Call Transcript
Revenue
$2.20M
▼ 8.2% YoY
Diluted EPS
$-49.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Curis Inc (CRIS) Q1 2023 Earnings Call Transcript
Revenue
$2.30M
▲ 11.7% YoY
Diluted EPS
$-47.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Curis Inc (CRIS) Q4 2022 Earnings Call Transcript
Revenue
$2.89M*
▼ 7.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Curis Inc (CRIS) Q3 2022 Earnings Call Transcript
Revenue
$2.83M
▼ 7% YoY
Diluted EPS
$-56.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Curis Inc (CRIS) Q2 2022 Earnings Call Transcript
Revenue
$2.39M
▲ 4.7% YoY
Diluted EPS
$-3.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Curis Inc (CRIS) Q1 2022 Earnings Call Transcript
Revenue
$2.06M
▼ 6% YoY
Diluted EPS
$-3.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Curis Inc (CRIS) Q4 2021 Earnings Call Transcript
Revenue
$3.13M*
▲ 3.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Curis Inc (CRIS) Q3 2021 Earnings Call Transcript
Revenue
$3.04M
▲ 10.8% YoY
Diluted EPS
$-2.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Curis Inc (CRIS) Q2 2021 Earnings Call Transcript
Revenue
$2.29M
▼ 3.1% YoY
Diluted EPS
$-2.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Curis Inc (CRIS) Q1 2021 Earnings Call Transcript
Revenue
$2.19M
▼ 19.2% YoY
Diluted EPS
$-2.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Curis Inc (CRIS) Q4 2020 Earnings Call Transcript
Revenue
$3.02M
▼ 8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Curis Inc (CRIS) Q3 2020 Earnings Call Transcript
Revenue
$2.74M
▼ 4% YoY
Diluted EPS
$-2.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Curis Inc (CRIS) Q2 2020 Earnings Call Transcript
Revenue
$2.36M
▲ 12.7% YoY
Diluted EPS
$-3.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Curis Inc (CRIS) Q1 2020 Earnings Call Transcript
Revenue
$2.71M
▲ 53.3% YoY
Diluted EPS
$-5.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-19
Curis Inc (CRIS) Q4 2019 Earnings Call
Revenue
$3.29M
▲ 19.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 1108205 CUSIP 231269408 13F (30d) 52 filings 29 filers Visit website Investor relations